ANTI-VEEV HUMANIZED ANTIBODY
The present disclosure relates to an anti-VEEV humanised antibody or a fragment thereof comprising a framework 1, 2, 3, 4, S or 6 CDR regions independently selected from SEQ ID Nos: 2, 3, 4, 5, 6 or 7 characterised in that the antibody or fragment comprises in the framework at least one amino acid,...
Saved in:
Main Authors | , , , |
---|---|
Format | Patent |
Language | English French |
Published |
31.03.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure relates to an anti-VEEV humanised antibody or a fragment thereof comprising a framework 1, 2, 3, 4, S or 6 CDR regions independently selected from SEQ ID Nos: 2, 3, 4, 5, 6 or 7 characterised in that the antibody or fragment comprises in the framework at least one amino acid, that positively influences the binding/activity of the antibody, from the original murine antibody 1A3B7, pharmaceutical composition comprising same, methods of preparing the antibody or fragment and use of the antibody or fragment in treatment or prophylaxis, in particular the treatment or prophylaxis of VEEV infection.
Cette invention concerne un anticorps anti-VEEV humanisé ou un fragment de celui-ci comprenant une charpente de 1, 2, 3, 4, 5 ou 6 régions CDR indépendamment choisies parmi les SEQ ID N°: 2, 3, 4, 5, 6 ou 7, caractérisé en ce que ledit anticorps ou fragment comprend, dans la charpente, au moins un acide aminé qui influence positivement la liaison/activité de l'anticorps, provenant de l'anticorps murin original 1A3B7. Cette invention concerne également une composition pharmaceutique le contenant, des procédés de préparation de l'anticorps ou du fragment et l'utilisation dudit anticorps ou fragment pour traiter ou prévenir, en particulier, pour traiter ou prévenir l'infection à VEEV. |
---|---|
Bibliography: | Application Number: WO2010GB01753 |